OZOBAX DS
Clinical safety rating
cautionComprehensive clinical and safety monograph for OZOBAX DS (OZOBAX DS).
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
| Metabolism | Hepatic metabolism via deamination; minor CYP450 involvement. |
| Excretion | Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5% |
| Half-life | Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20-30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 20-30% bound to serum albumin. |
| Volume of Distribution | 0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | Oral: 95-100% (well absorbed); intravenous: 100%. |
| Onset of Action | Oral: 0.5-1 hour; peak effect at 1-2 hours. |
| Duration of Action | 6-8 hours based on minimum inhibitory concentration (MIC) for susceptible pathogens; prolonged in renal impairment. |
| Molecular Weight | 504.6 |
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30–59 mL/min/1.73 m²: 300 mg twice daily. eGFR 15–29 mL/min/1.73 m²: 200 mg twice daily. eGFR <15 mL/min/1.73 m²: 200 mg once daily. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: 400 mg per day in divided doses. Child-Pugh Class C: not recommended. |
| Pediatric use | Children (6–12 years): 10–15 mg/kg per dose twice daily, max 600 mg daily. Adolescents (12–18 years): same as adult dosing. |
| Geriatric use | Start at the lower end of the dosing range (600 mg/day in divided doses) and titrate based on renal function; monitor for side effects. |
| 1st trimester | No adequate studies in humans; animal studies not available. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | No adequate studies in humans; animal studies not available. Use only if potential benefit justifies potential risk to fetus. |
| 3rd trimester | No adequate studies in humans; animal studies not available. Use only if potential benefit justifies potential risk to fetus. |
Clinical note
Comprehensive clinical and safety monograph for OZOBAX DS (OZOBAX DS).
| Placental transfer | No published data available; molecular weight suggests placental transfer expected. |
| Breastfeeding | It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. Discontinue breastfeeding or the drug, taking into account the importance of the drug to the mother. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to increase the incidence of omphalocele (ventral hernia) in fetuses of rats given approximately 3 times the maximum human dose. In rabbits, an increased incidence of incomplete ossification of sternal centers was observed. Cases of neonatal withdrawal syndrome have been reported with chronic maternal use during the third trimester, presenting as hypertonia, tremor, and seizures. Therefore, use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid use in the first trimester unless clearly needed. |
| Fetal Monitoring | Monitor maternal blood pressure, respiratory rate, and level of sedation. Assess for signs of muscle weakness or ataxia. In the fetus, monitor fetal heart rate and growth in cases of prolonged use. After delivery, monitor the neonate for signs of baclofen withdrawal (e.g., hypertonia, irritability, seizures) if the mother used the drug chronically during the third trimester. |
| Fertility Effects | In animal studies, baclofen did not impair fertility in rats at doses up to 3 times the maximum human dose. Human data are lacking. No specific effects on human fertility have been reported. However, patients with underlying conditions (e.g., multiple sclerosis) may have fertility issues unrelated to the drug. |
■ FDA Black Box Warning
Abrupt discontinuation may precipitate withdrawal syndrome, including severe hyperthermia, altered mental status, and muscle rigidity, which can be life-threatening. Taper slowly.
| Serious Effects |
Hypersensitivity to any component of the formulation
| Precautions | Risk of withdrawal syndrome with abrupt cessation, Dose-dependent sedation and dizziness may impair ability to drive or operate machinery, May exacerbate psychiatric disorders; use with caution in patients with depression or schizophrenia, Renal impairment requires dose adjustment, Respiratory depression risk, especially with concomitant CNS depressants |
| Food/Dietary | No specific food interactions; however, taking with food may reduce gastrointestinal discomfort. |
| Clinical Pearls | OZOBAX DS (baclofen) is a GABA-B receptor agonist used for spasticity. Dosage titration is critical to avoid adverse effects. Abrupt discontinuation can cause withdrawal (hallucinations, seizures). Monitor for respiratory depression, especially in elderly or renal impairment. Consider dose adjustment in renal impairment (CrCl <30 mL/min). |
| Patient Advice | Take exactly as prescribed; do not stop suddenly. · May cause drowsiness or dizziness; avoid driving until you know how it affects you. · Avoid alcohol as it may worsen side effects. · Report any signs of withdrawal: confusion, hallucinations, seizures. · Take with food to reduce stomach upset. |
Loading safety data…